Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. It has licensed ALXN-1840, a candidate for the treatment of Wilson disease that was previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results